The cold tumour paradox is resolved by a hierarchical twin engine: rare genomic outliers permit initial persistence, but local IFN-γ/PD-L1 feedback dominates resistance, identifying induction capacity as the primary therapeutic target for JAK/STAT inhibition combined with ICB. Here, SOAT1 is linked to neoplasm.